|
    VRTX U.S.: Nasdaq

    Vertex Pharmaceuticals Inc.

    VRTXUS
    After Hours
    Last Updated: Sep 17, 2021 6:27 p.m. EDT Delayed quote

    $ 187.00

    -1.30 -0.69%
    After Hours Volume: 261.67K
    Close Chg Chg %
    $188.30 1.20 0.64%
    Advanced Charting
    Volume: 2.21M 65 Day Avg: 2.07M
    107% vs Avg
    184.78 Day Range 188.54
    184.78 52 Week Range 280.99

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    VRTX Overview

    Performance

    5 Day
    • -0.14%
    1 Month
    • -3.85%
    3 Month
    • 0.24%
    YTD
    • -20.33%
    1 Year
    • -29.05%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 27 Full Ratings

    Recent News

    Read full story

    Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

    Read full story

    Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

    Read full story

    Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market

    Read full story

    Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

    Read full story

    Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

    Read full story

    Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

    Read full story

    Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market

    Vertex Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus

    Read full story

    Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

    Read full story

    Moderna stock extends rally after price target gets a 77% boost at Morgan Stanley

    Read full story

    Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

    Vertex Pharmaceuticals downgraded to underweight from equal weight at Morgan Stanley

    Read full story

    Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market

    Read full story

    Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day

    Read full story

    Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market

    Read full story

    Vertex Pharmaceuticals Inc. stock rises Tuesday, outperforms market

    Read full story

    Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market

    Read full story

    These 20 ‘left behind’ stocks among the S&P 500 are expected to rise up to 59% over 12 months

    Read full story

    Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market

    Read full story

    Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market

    Calamos Growth and Income Portfolio Buys AbbVie Inc, Sells Fortive Corp, Vertex Pharmaceuticals ...

    on GuruFocus.com

    Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

    on Zacks.com

    Loomis Sayles Growth Portfolio Buys Vertex Pharmaceuticals Inc

    on GuruFocus.com

    Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

    on Zacks.com

    Here's Why You Should Retain QIAGEN (QGEN) Stock For Now

    on Zacks.com

    3 Explosive Biotech Stocks That Could 10X in 10 Years

    on Motley Fool

    7 Gene Editing Stocks Promising to Change our DNA

    on InvestorPlace.com

    5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now

    on Zacks.com

    ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

    on Zacks.com

    Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence

    on Zacks.com

    Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance

    on Zacks.com

    Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran

    on Zacks.com

    3 Crash-Ready Stocks to Buy in September

    on Motley Fool

    3 Nasdaq 100 Stocks Begging to Be Bought in September

    on Motley Fool

    Aspiration Funds Buys TJX Inc, Vertex Pharmaceuticals Inc, Bank OZK, Sells AGCO Corp, ...

    on GuruFocus.com

    2 Top Biotech Stocks to Buy Right Now

    on Motley Fool

    2 Biotech Stocks That Are Better Buys Than Moderna

    on Motley Fool

    Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

    on Zacks.com

    3 Top Healthcare Stocks to Buy for September

    on Motley Fool

    3 Red-Hot Healthcare Stocks to Buy in September

    on Motley Fool

    Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

    Competitors

    Name Chg % Market Cap
    AbbVie Inc. -0.32% $190.38B
    Arcturus Therapeutics Holdings Inc. 1.25% $1.43B
    Krystal Biotech Inc. 4.78% $1.31B
    4D Molecular Therapeutics Inc. 3.02% $939.19M
    Eloxx Pharmaceuticals Inc. 6.86% $161.2M
    Competitor Data Provided ByCapital Cube Logo